The Focused Analysis of COVID-19 RNA-based vaccines
DOI:
https://doi.org/10.54097/hset.v36i.6113Keywords:
RNA-based Vaccines, mRNA Vaccines, COVID-19.Abstract
The COVID-19 virus has rapidly spread over the whole world and has now been declared a pandemic since the first cases of SARS-CoV-2 infection, also known as COVID-19, were found in Wuhan, China. It is undeniable that the only effective method to reduce COVID-19-related morbidity and mortality is to prevent infection through widespread vaccination. Various COVID-19 vaccines have been developed to date, many of which have been approved for use in the prevention of COVID-19. The era of RNA vaccines has come since December 2020, when two RNA-based vaccines -- from German pharmaceutical company BioNTech and US pharmaceutical company Moderna respectively--received emergency use authorizations from regulators in several countries to fight COVID-19. RNA-based vaccines were the first to be created and approved for use in humans, and they continue to play a crucial role in the global effort to fight the illness. This essay will introduce the efficacy, adverse reactions, production, and encountered limitations of existing RNA-based COVID-19 vaccines, and also predict the possible development direction of RNA-based vaccines in the future.
Downloads
References
Dai L, Gao G F. Viral targets for vaccines against COVID-19 [J]. Nature Reviews Immunology, 2020, 21: 73–82.
Islam N, Sheils N E, Jarvis M S, et al. Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine [J]. Nature Communications, 2022, 13(1): 2377.
Machado B A S, Hodel K V S, Fonseca L M, et al. The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview [J]. Vaccines, 2021, 9(11): 1345.
Borah P, Deb P K, Al-Shar’i N A, et al. Perspectives on RNA Vaccine Candidates for COVID-19 [J]. Frontiers in Molecular Biosciences, 2021, 8: 63524.
Jain S, Venkataraman A, Wechsler M E, et al. Messenger RNA-based Vaccines: Past, Present, and Future Directions in the Context of the COVID-19 Pandemic [J]. Advanced Drug Delivery Reviews, 2021, 179: 114000.
Ball R, Bajaj P, Whitehead K. Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization [J]. International Journal of Nanomedicine, 2016, 12: 305–315.
Polack F P, Thomas S J, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine [J]. New England Journal of Medicine, 2020, 383(27): 2603–2615.
Liu M A. A Comparison of Plasmid DNA and mRNA as Vaccine Technologies [J]. Vaccines, 2019, 7(2): 37.
Pepini T, Pulichino A-M, Carsillo T, et al. Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design [J]. Journal of Immunology, 2017, 198(10): 4012–4024.
Fraiman J, Erviti J, Jones M, et al. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults [J]. Vaccine, 2022, 40: 5798-5805.
Lundstrom K. Latest development on RNA-based drugs and vaccines [J]. Future Science OA, 2018, 4(5): FSO300.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
